Therefore, we extended our assessment of CAP2, DLG1, and ADAM10 gene and protein expression levels to the post-mortem superior frontal gyrus (SFG) of patients affected by neurodegenerative diseases such as PD and AD. This evidence concerns the gene DLG1 and Parkinson disease.